SER100

also known as Ac-ryyrwkkkkkkk-nh2 · ZP120

Developed for: congestive heart failure
Investigated by: Serodus AS · Smerud Medical Research International AS · Syneos Health · The Research Council of Norway · Zealand Pharma

today NCT01987284 · Ph 2 NCT00283361 · Ph 2

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01987284	Oct 2013 → Jul 2014	—	Serodus AS	Completed	No outcome recorded
Phase 2	NCT00283361	Jan → Dec 2006	congestive heart failure	Zealand Pharma	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	SER100	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01987284 ↗
Known as	Ac-ryyrwkkkkkkk-nh2	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297428 ↗
Known as	ZP120	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00283361 ↗
Modality	Protein / enzyme biologic	— CHEMBL4297428 ↗
Route	Intravenous	“ZP120 I.V. Infusion” NCT00283361 ↗